223镭时代的骨转移性疾病治疗评估
本文综述了在223Ra治疗转移性去势抵抗性前列腺癌骨转移时,如何选择最佳影像学方法和评估时机。文章讨论了18F-FDG、18F-FCH、68Ga-PSMA和18F-NaF等PET/CT示踪剂在弥补传统影像局限方面的研究,并提及诊疗一体化概念及18F-氟化物PET/CT用于筛选223Ra治疗患者的示例。
要点
- 223Ra已获FDA和欧洲药品管理局批准用于治疗伴疼痛性骨受累的转移性去势抵抗性前列腺癌。
- 18F-FDG、18F-FCH、68Ga-PSMA和18F-NaF等PET/CT示踪剂已被研究用于弥补传统影像的局限。
- 诊疗一体化概念中,与治疗性示踪剂性质相似的诊断性示踪剂可精确评估治疗可能性和疗效。
核心结论
- 本综述考察了与223Ra治疗骨转移性疾病评估相关的最新文献。
- 诊疗一体化概念中,与治疗性示踪剂性质相似的诊断性示踪剂可精确评估治疗可能性和疗效。
研究设计与样本
- 综述,考察与223Ra治疗骨转移性疾病评估相关的最新发表文献。
主要发现
- 223Ra已获FDA和欧洲药品管理局批准用于治疗伴疼痛性骨受累的转移性去势抵抗性前列腺癌。
- 18F-FDG、18F-FCH、68Ga-PSMA和18F-NaF等PET/CT示踪剂已被研究以弥补传统影像模式的局限。
- 18F-氟化物PET/CT联合用于评估223Ra治疗可能性是诊断性检查用于选择靶向治疗的示例。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Defining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient's management. METHODS: 223Ra (Xofigo®, formerly Alpharadin) has been approved by the FDA and European Medicines Agency for treatment of metastatic castration-resistant prostate cancer with painful osseous involvement. RESULTS: PET/CT imaging using various radiotracers such as 18F-FDG, 18F-FCH, 68Ga-PSMA and 18F-NaF have been investigated to mitigate the limitations of conventional imaging modalities. Diagnostic radiotracers that have properties similar to a therapeutic radiotracer will precisely assess of the possibility and efficacy of a treatment; this is the theranostic concept. An example of a diagnostic test employed for selecting targeted therapy is the combined use of 18F-fluoride PET/CT for evaluation of possible therapy with 223Ra. CONCLUSION: This review examines the most recent publications related to this topic.
引用
- Etchebehere E, Brito AE, Rezaee A, et al. Therapy assessment of bone metastatic disease in the era of 223radium. Eur J Nucl Med Mol Imaging. 2017. PMID: 28567494. doi:10.1007/s00259-017-3734-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。